Fig. 7: Both miR-21 and Spry2 were closely correlated with clinical pathological features in PDAC patients.
From: miR-21 promotes EGF-induced pancreatic cancer cell proliferation by targeting Spry2
a Representative images of the miR-21 level in normal pancreatic tissues and matched pancreatic cancer tissues. b miR-21 expression in T1 and T2 vs T3, N0 vs N1, and AJJC stage 0-IIA vs IIB-IV. c Representative images of Spry2 expression in normal pancreatic tissues and matched pancreatic cancer tissues. d Spry2 expression in grade I-II vs grade III, T1 and T2 vs T3, N0 vs N1, AJJC stage 0-IIA vs IIB-IV. e The OS of patients with high miR-21 vs low miR-21 expression. f The OS of patients with high Spry2 vs low Spry2 expression. All data are represented as the mean ± SD. *P <0.05; **P < 0.01
